ProCE Banner Activity

DESTINY-Lung02: Phase II Trial of Trastuzumab Deruxtecan in Patients With Previously Treated HER2-Mutated Metastatic NSCLC

Conference Coverage

In the primary analysis of DESTINY-Lung02, trastuzumab deruxtecan dosed at 5.4 mg/kg Q3W was associated with an ORR of 49.0% and a more tolerable safety profile compared with trastuzumab deruxtecan dosed at 6.4 mg/kg Q3W in the second-line or later setting for HER2-mutated metastatic NSCLC.

Released: September 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc